title: Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.
abstract: OBJECTIVE
  To retrospectively assess the incidence of radiation dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) who received primary radiotherapy in combination with cetuximab in a curative intent.
  
  
  METHODS
  A total of 112 consecutively treated patients who received cetuximab in combination with radiotherapy at the Departments of Radiotherapy at the Medical University in Vienna and the Hospital Hietzing (Vienna) were analyzed. Radiotherapy was administered either as conventional radiotherapy (70 Gy in 7 weeks) or using a concomitant boost protocol (72 Gy in 6 weeks). The incidence of dermatitis and mucositis within the radiation portals in 103 eligible patients was compared with a historical control group treated at the Medical University of Vienna as well as with published data.
  
  
  RESULTS
  The incidence of grade 1/2, 3, and 4 dermatitis was 57%, 29%, and 1% in the radiotherapy plus cetuximab treated collective. The incidence of grade 1/2, 3, and 4 mucositis was 37%, 47%, and 4%, respectively. The incidence of grade 3 dermatitis during concurrent radiotherapy plus cetuximab was 29% in our patient collective. Only one case of grade 4 dermatitis was observed.
  
  
  CONCLUSIONS
  These results do not statistically differ significantly from the incidence reported in the Bonner trial and indicate that cetuximab in combination with radiotherapy is well tolerated.
authors: Department of Radiotherapy, Medical University of Vienna, Austria. Edgar.selzer@meduniwien.ac.at
authors: Edgar
authors: E
authors: Selzer
authors: Susanne
authors: S
authors: Liederer
authors: Christiane
authors: C
authors: Lemaire
authors: Gerhard
authors: G
authors: Kren
authors: Dejan
authors: D
authors: Radonjic
authors: Gabriela
authors: G
authors: Kornek
authors: Thomas
authors: T
authors: Knocke
authors: Richard
authors: R
authors: Pötter
authors: Barbara
authors: B
authors: Bachtiary
references: Ann Oncol. 2009 May;20 Suppl 4:121-2
references: 19454430
references: Ann Oncol. 2008 Jan;19(1):142-9
references: 17785763
references: Oncologist. 2008 Aug;13(8):899-910
references: 18701764
references: Cases J. 2009 Jan 07;2(1):25
references: 19128507
references: Am J Clin Oncol. 2009 Oct;32(5):472-6
references: 19487913
references: Strahlenther Onkol. 2009 Jan;185(1):8-18
references: 19224142
references: N Engl J Med. 2008 Sep 11;359(11):1143-54
references: 18784104
references: Strahlenther Onkol. 2009 Dec;185(12):775-81
references: 20013086
references: Strahlenther Onkol. 2010 May;186(5):255-61
references: 20437016
references: Radiother Oncol. 2009 Feb;90(2):166-71
references: 18977050
references: Radiother Oncol. 2009 Feb;90(2):172-6
references: 18976827
references: Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):676-81
references: 18355979
references: N Engl J Med. 2001 Dec 27;345(26):1890-900
references: 11756581
references: Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):974-84
references: 17967298
references: Cutan Ocul Toxicol. 2009;28(1):41-4
references: 19514925
references: Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22
references: 11597400
references: Lancet Oncol. 2010 Jan;11(1):21-8
references: 19897418
references: N Engl J Med. 2007 Aug 2;357(5):514-5
references: 17671265
references: N Engl J Med. 2008 Sep 11;359(11):1116-27
references: 18784101
references: J Clin Oncol. 2006 Mar 1;24(7):1072-8
references: 16505426
references: Strahlenther Onkol. 2009 Oct;185(10):682-8
references: 19806334
references: Strahlenther Onkol. 2009 Oct;185(10):675-81
references: 19806333
references: Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16
references: 10924966
references: Radiat Oncol. 2008 Jan 28;3:5
references: 18226196
references: N Engl J Med. 2006 Feb 9;354(6):567-78
references: 16467544
references: Radiother Oncol. 2009 Jul;92(1):4-14
references: 19446902
references: Strahlenther Onkol. 2008 Feb;184(2):105-10
references: 18259703